Vyome Holdings (HIND) Non Operating Income (2024 - 2026)
Vyome Holdings (HIND) posted Non Operating Income of $142883.0 for Q2 2026, down 1.06% on a QoQ basis from $144419.0 in Q1 2026, and up 826.07% year-over-year from $15429.0 in Q2 2025.
Powered by 
Analysis
Vyome Holdings (HIND) Non Operating Income (2024 - 2026) Analysis & Trends
Vyome Holdings has reported Non Operating Income for 3 years, with the latest figure at $142883.0 in Q2 2026.
- On a quarterly basis, Non Operating Income rose 826.07% year-over-year to $142883.0 in Q2 2026; TTM through Jun 2026 was $341706.0, a 186.1% increase from a year earlier, with the FY2025 full-year figure at -$25143.0, up 94.3% from the prior year.
- Non Operating Income was $142883.0 for Q2 2026 at Vyome Holdings, down from $144419.0 in the prior quarter.
- The five-year high for Non Operating Income was $474000.0 in Q2 2024, with the low at -$266794.0 in Q3 2024.
- Average Non Operating Income over 3 years is $44981.4, with a median of $23214.5 recorded in 2024.
- The sharpest annual moves came in 2025 and 2026: Non Operating Income plunged 406.37% in 2025, then surged 826.07% in 2026.
- Over 3 years, Non Operating Income stood at -$50551.0 in 2024, then surged by 249.14% to $75394.0 in 2025, then surged by 89.52% to $142883.0 in 2026.
- The last three Non Operating Income figures came in at $142883.0 (Q2 2026), $144419.0 (Q1 2026), and $75394.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Vyome Holdings | 14.46 Mn | 6.57 Mn | 11,658.00 | 142,883.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 142,883.00 |
| Mar 31, 2026 | 144,419.00 |
| Dec 31, 2025 | 75,394.00 |
| Sep 30, 2025 | -20,990.00 |
| Jun 30, 2025 | 15,429.00 |
| Mar 31, 2025 | -94,976.00 |
| Dec 31, 2024 | -50,551.00 |
| Sep 30, 2024 | -266,794.00 |
| Jun 30, 2024 | 474,000.00 |
| Mar 31, 2024 | 31,000.00 |